BioPharma Credit PLC
BOPCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $124 | $160 | $214 | $126 |
| % Growth | -22.1% | -25.3% | 69.1% | – |
| Cost of Goods Sold | $26 | $25 | $34 | $16 |
| Gross Profit | $124 | $110 | $184 | $88 |
| % Margin | 100% | 69.2% | 86.2% | 69.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $2 | $2 | $2 | $3 |
| Operating Income | $122 | $108 | $182 | $85 |
| % Margin | 98.2% | 67.9% | 85.3% | 67.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $122 | $108 | $182 | $85 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $122 | $108 | $182 | $85 |
| % Margin | 98.2% | 67.9% | 85.3% | 67.2% |
| EPS | 0.1 | 0.083 | 0.13 | 0.062 |
| % Growth | 20.8% | -36.3% | 110.4% | – |
| EPS Diluted | 0.1 | 0.083 | 0.13 | 0.062 |
| Weighted Avg Shares Out | 1,222 | 1,309 | 1,374 | 1,374 |
| Weighted Avg Shares Out Dil | 1,222 | 1,309 | 1,374 | 1,374 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $4 | $1 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$122 | -$108 | -$182 | -$85 |
| EBITDA | $122 | $0 | $0 | $0 |
| % Margin | 98.2% | 0% | 0% | 0% |